BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Unilens Vision Inc. Announces National Roll-Out of Disposable C-Vue® HydraVUE™ Multifocal Silicone Hydrogel Contact Lenses


2/22/2013 8:29:42 AM

LARGO, FL--(Marketwire - February 21, 2013) - Unilens Vision Inc. (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today announced the launch of its new silicone hydrogel disposable C-Vue® HydraVUEMultifocal contact lens for monthly replacement. The new product continues to incorporate Unilens' highly developed, world-class patented Multifocal design technology in a silicone hydrogel material, which offers the benefit of higher oxygen transmissibility for better eye health.

"C-Vue HydraVUE Multifocal contact lenses in silicone hydrogel provide vision correction for presbyopia, an age-related eye condition that causes a person's 'near vision' to deteriorate, typically after reaching the age of 40," stated Kelly McKnight, Vice President of Sales and Marketing at Unilens Vision Inc. "It is C-Vue's proven, patented rapid transition zone design technology, incorporated within the lens itself, that provides for excellent near, far and everywhere in-between visual outcomes without the need to wear bifocal or reading glasses. The new silicone hydrogel material is characterized by greater oxygen transmissibility for better eye heath and overall comfort."

The new monthly replacement lenses, which are available in High and Low ADD Power Ranges (from +6.00 to -10.00), will be sold exclusively to independent eye care professionals. Unilens will provide eye care professionals with an attractive and user-friendly display cabinet and trial program with a 120-Day Performance Guarantee on the lenses.

"As the number of persons with presbyopia continues to grow at a faster rate than America's population as a whole due to demographic trends, the new C-Vue HydraVUE Multifocal, now available with our updated trial cabinet program, will provide independent practitioners with a silicone hydrogel multifocal contact lens option that contributes to patient retention and practice profitability," noted Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "We are very excited about the launch of this new product, which we believe will be enthusiastically received by licensed optical professionals and contact lens wearers."

About Unilens Vision Inc. - "The Independent Eye Care Professionals' Contact Lens Company"

Established in 1989 and located in Largo, Florida, Unilens Vision Inc., through its wholly-owned subsidiaries Unilens Corp., USA and Unilens Vision Sciences Inc., develops, licenses, manufactures, distributes and markets contact lenses, primarily under the C-Vue® brand, directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTCQB under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI".

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


For more information, please contact:

Kelly McKnight
Unilens Vision Inc.
(727) 544-2531
Kelly.mcknight@unilens.com

or

RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
info@rjfalkner.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->